April 22nd 2024
In separate, live virtual events, Kami J. Maddocks, MD, and Sairah Ahmed, MD, discussed the use of loncastuximab tesirine for a patient with later-line diffuse large B-cell lymphoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Lunning Discusses Defining and Approaching Treatment for Early-Relapsed DLBCL
October 10th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew A. Lunning, DO, and participants discussed how they approach treatment for a patient with diffuse large B-cell lymphoma who relapsed 8 months after primary therapy.
Read More
Bispecific T-Cell Engagers Emerge as Later-Line Therapies for DLBCL
October 2nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Medhi H. Hamadani, MD, discussed the bispecific T-cell engagers epcoritamab and glofitamab and how they fit into the treatment algorithm for patients with diffuse large B-cell lymphoma. This is the second of 2 articles based on this event.
Read More
Phillips Discusses Treatment Options for Early-Relapsed DLBCL
September 22nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Tycel J. Phillips, MD, and participants discussed treatment options for a patient with diffuse large B-cell lymphoma who progressed after 8 months on first-line therapy and prefers to receive outpatient therapy.
Read More
Reviewing Options After CAR T-Cell Therapy Progression in R/R DLBCL
September 20th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Mehdi H. Hamadani, MD, discussed the efficacy of therapies for diffuse large B-cell lymphoma after progression on chimeric antigen receptor T-cell therapy. This is the first of 2 articles based on this event.
Read More
Evaluating the Role of Loncastuximab in Relapsed/Refractory DLBCL
August 8th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Brad Haverkos, MD, and other participants discussed the role of loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma. This is the second of 2 articles based on this event.
Read More
Considerations for Third-Line Therapy for Relapsed/Refractory DLBCL
July 31st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Brad Haverkos, MD, and other participants discussed the choice of treatment options for a patient with relapsed/refractory diffuse large B-cell lymphoma who previously received R-CHOP and pola-BR.
Read More
Treatment Considerations in Primary Refractory vs Early-Relapsed DLBCL
July 25th 2023In the first article of a 2-part series, Joseph M. Tuscano, MD, discusses at a virtual live event with fellow clinicians how to define early-relapsed or primary refractory diffuse large B-cell lymphoma and how this impacts treatments for this patient population.
Read More
Physicians Discuss Roles of Later-Line Therapies in DLBCL
July 14th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew Matasar, MD, MS, discussed with oncologists how they use loncastuximab tesirine and tafasitamab/lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Efficacy Data Support Loncastuximab as Third-Line DLBCL Treatment
June 23rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew Matasar, MD, MS, discussed the data supporting the safety and efficacy of loncastuximab tesirine in patients with diffuse large B-cell lymphoma. This is the first of 2 articles based on this event.
Read More
Navigating CAR T-Cell Therapies in Relapsed/Refractory DLBCL
June 15th 2023At a live, virtual event held in partnership with Healthcare Research & Analytics®, Alex F. Herrera Jr, MD, discussed the growing influence of chimeric antigen receptor T-cell therapies in patients with diffuse large B-cell lymphoma.
Read More
Physicians Respond to 5-Year Tafasitamab/Lenalidomide Data for R/R DLBCL
June 6th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen J. Schuster, MD, discussed the use of tafasitamab plus lenalidomide in patients with diffuse large B-cell lymphoma including managing adverse events and treating patients after disease progression.
Read More
Behind the FDA Approval: Subcutaneous Epcoritamab for R/R DLBCL
May 19th 2023In an interview with Targeted Oncology, Tycel Phillips, MD, discussed what led to the FDA approval of subcutaneous epcoritamab for patients with relapsed/refractory diffuse large B-cell lymphoma and how it adds to the current treatment landscape.
Read More
Long-Term Combination Data Show Most Benefit in Second-Line DLBCL
May 16th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen A. Schuster, MD, discussed the 5-year outcomes of the L-MIND trial of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Roundtable Discussion: Khan Reviews Systemic Therapy for Relapsed/Refractory DLBCL
April 24th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Cyrus Khan, MD, discussed the case of a patient with relapsed/refractory diffuse large B-cell lymphoma who was referred for chimeric antigen receptor T-cell therapy and was place on a waiting list for treatment.
Read More
Reviewing Key Efficacy and Safety Data for Tafasitamab Plus Lenalidomide in DLBCL
April 14th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Gilles Salles, MD, discussed the study results and practical considerations for the use of tafasitamab plus lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
When to Use Second-Line CAR T-cell Therapy for Relapsed/Refractory DLBCL
March 24th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Gilles Salles, MD, discussed when to use CAR T-cell therapy in the second-line setting for patients with relapsed/refractory diffuse large B-cell lymphoma and the outcomes of trials of these agents. This is the first of 2 articles based on this event.
Read More
Dosing and Management: Optimal Use of Tafasitamab/Lenalidomide for Relapsed DLBCL
March 22nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Bruce D. Cheson, MD, discussed adverse event management and dosing strategies for patients receiving tafasitamab and lenalidomide for diffuse large B-cell lymphoma.
Read More
Zamtocabtagene Autoleucel Shows High Response Rates in Relapsed/Refractory DLBCL
February 16th 2023Findings from the phase 2 DALY II USA trial showed that the 28-day objective response rate was 78% with freshly administered zamtocabtagene autoleucel, exceeding the prespecified efficacy threshold for interim analysis.
Read More
Preliminary VITALIZE Results Show CRs to IO Combination in R/R DLBCL
February 15th 2023Early results announced from the VITALIZE study show efficacy and safety of maveropepimut-S plus pembrolizumab and low-dose, intermittent cyclophosphamide for patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Bridging Options for CAR T-Cell Therapy in R/R DLBCL
January 6th 2023During a Targeted Oncology case-based roundtable event, Christopher R. Flowers, MD, MS, discussed the choice of bridging therapy for a patient with relapsed/refractory diffuse large B-cell lymphoma who may receive CAR (chimeric antigen receptor) T-cell therapy. This is the second of 2 articles based on this event.
Read More
Real-World Experience With Referral and Access to CAR T-Cell Therapy
December 30th 2022During a Targeted Oncology case-based roundtable event, Christopher R. Flowers, MD, MS, discussed with participants their experiences referring patients for chimeric antigen receptor T-cell therapy and using bridging therapy. This is the first of 2 articles based on this event.
Read More
Shifting Treatment Paradigm in DLBCL Reflects Changes for CAR T-Cell Therapy, Polatuzumab
December 20th 2022The combination of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone is moving into the frontline setting for patients with diffuse large B-cell lymphoma.
Read More
Matasar Looks at Various Treatment Options in the DLBCL Setting for Transplant-Ineligble Patients
December 19th 2022During a Targeted Oncology case-based roundtable event, Matthew Matasar, MD, MS, discussed the case of a patient with diffuse large B-cell lymphoma who relapsed 18 months following frontline combination therapy.
Read More
Phillips Evaluates Second-Line Therapy Options for R/R DLBCL
December 14th 2022During a Targeted Oncology case-based roundtable event, Tycel Phillips, MD, discussed available therapies for a patient with relapsed/refractory diffuse large B-cell lymphoma including CAR T-cell therapy and combination systemic therapies.
Read More